The Technical Analyst
Outlook Therapeutics Inc [OTLK]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Outlook Therapeutics Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals
-3.72% $8.29
America/New_York / 18 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 178.93 mill |
| EPS: | -4.00 |
| P/E: | -2.07 |
| Earnings Date: | May 12, 2024 |
| SharesOutstanding: | 21.58 mill |
| Avg Daily Volume: | 0.653 mill |
| RATING 2024-04-18 |
|---|
| C |
| Sell |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Sell | |
| Return On Equity: | Strong Buy | |
| Return On Asset: | Strong Sell | |
| DE: | Strong Sell | |
| P/E: | Sell | |
| Price To Book: | Strong Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -2.07 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.35x |
| Company: PE -2.07 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$-0.972 (-111.73%) $-9.26 |
| Date: 2024-04-18 |
| Expected Trading Range (DAY) |
|---|
|
$ 6.84 - 9.76 ( +/- 17.63%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-04-15 | Syntone Ventures Llc | Buy | 714 286 | Common Stock |
| 2024-04-15 | Syntone Ventures Llc | Buy | 1 071 429 | Warrant (Right to Buy) |
| 2024-03-28 | Haddadin Yezan Munther | Buy | 1 882 | Common Stock |
| 2024-03-20 | Trenary C Russell Iii | Buy | 455 000 | Stock Option (Right to Buy) |
| 2024-03-20 | Evanson Jeff | Buy | 25 000 | Stock Option (Right to Buy) |
| INSIDER POWER |
|---|
| 87.16 |
| Last 99 transactions |
| Buy: 132 469 020 | Sell: 31 433 684 |
Forecast:
16:00 - $8.28
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $8.28
Forecast 2: 16:00 - $8.28
Forecast 3: 16:00 - $8.28
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $8.29 (-3.72% ) |
| Volume | 0.233 mill |
| Avg. Vol. | 0.653 mill |
| % of Avg. Vol | 35.72 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For OTLK
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
OTLK
Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with IPCA Laboratories Limited; Laboratorios Liomont, S.A. de C.V.; BioLexis Pte. Ltd.; and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.
Latest Press Releases
2024-04-15 16:15:00 - Press Release
Outlook Therapeutics® Announces Closing Of Private Placement Of $5.0 Million
Iselin, n.j., april 15, 2024 (globe newswire) -- outlook therapeutics, inc. (nasdaq: otlk), a biopharmaceutical company working to achieve the first approval for an ophthalmic formulation of bevacizumab for the treatment of retinal diseases in the us and the eu, today announced that it has closed its previously announced private placement with syntone ventures, llc, an existing stockholder, for upfront gross proceeds of approximately $5.0 million from the issuance and sale of shares of the company's common stock and accompanying warrants, before deducting offering expenses. in addition, outlook therapeutics has the potential to receive additional gross proceeds of up to $8 million upon the full cash exercise of the warrants issued in the private placement, before deducting offering expenses.
2024-03-22 07:35:00 - Press Release
Outlook Therapeutics® Receives European Union Positive Chmp Opinion For Ons-5010 As A Treatment For Wet Amd
Iselin, n.j., march 22, 2024 (globe newswire) -- outlook therapeutics, inc. (nasdaq: otlk), a biopharmaceutical company working to achieve the first approval for an ophthalmic formulation of bevacizumab for the treatment of retinal diseases in the us and the eu, today announced that the committee for medicinal products for human use (chmp) of the european medicines agency (ema) has issued a positive opinion concerning the authorization of ons-5010/lytenava™ (bevacizumab gamma), an investigational ophthalmic formulation of bevacizumab for the treatment of wet age-related macular degeneration (wet amd) in the eu. outlook therapeutics is assessing both direct commercialization of the product and partnering in europe on a country-by-country basis.
2024-03-18 17:10:00 - Press Release
Outlook Therapeutics® Announces Closing Of Private Placement Of Up To $159 Million
Iselin, n.j., march 18, 2024 (globe newswire) -- outlook therapeutics, inc. (nasdaq: otlk), a biopharmaceutical company working to achieve the first approval for an ophthalmic formulation of bevacizumab for the treatment of retinal diseases in the us and the eu, today announced that it has closed its previously announced private placement, for upfront gross proceeds of approximately $60 million from the issuance and sale of shares of the company's common stock and accompanying warrants, before deducting placement agent fees and offering expenses. outlook therapeutics has the potential to receive additional gross proceeds of up to $99 million upon the full cash exercise of the warrants issued in the private placement, before deducting placement agent fees and offering expenses.
2024-03-12 08:05:00 - Press Release
Outlook Therapeutics® Announces Effective Date For 1-for-20 Reverse Stock Split
Iselin, n.j., march 12, 2024 (globe newswire) -- outlook therapeutics, inc. (nasdaq: otlk) (the “company”), a biopharmaceutical company working to achieve fda approval for the first ophthalmic formulation of bevacizumab for the treatment of retinal diseases, today announced that a 1-for-20 reverse stock split of its outstanding shares of common stock will be effective on march 14, 2024.
2024-02-14 08:05:00 - Press Release
Outlook Therapeutics® Reports Financial Results For First Quarter Fiscal Year 2024 And Provides Corporate Update
Iselin, n.j., feb. 14, 2024 (globe newswire) -- outlook therapeutics, inc. (nasdaq: otlk), a biopharmaceutical company working to achieve regulatory approval for the first ophthalmic formulation of bevacizumab for the treatment of retinal diseases, today announced financial results for first quarter fiscal year 2024 and provided a corporate update.
Latest News
2024-04-15 12:54:18 - InvestorPlace
Biotech on a Budget: 7 Stocks Under $10 With Huge Potential
The broader medical therapeutic sector is already volatile so it stands to reason in some sense to consider under-$10 biotech stocks. Imagine you acquired shares of a popular, richly priced enterprise, only for the underlying security to suffer due to a poor clinical result.
2024-03-31 09:25:35 - Seeking Alpha
Outlook Therapeutics: De-Risked Regulatory Tracks Are Lining Up For Possible ONS-5010 Approval
The positive CHMP opinion could mean possible European Approval; European Commission expected to decide upon approval for this in the next few months. Phase 3 NORSE EIGHT study underway using ONS-5010 for the treatment of patients with Wet-AMD; Data expected to be released in Q4 of 2024. Pending the primary endpoint of BCVA in NORSE EIGHT being met with statistical significance, BLA filing of ONS-5010 for Wet-AMD expected in 2024.
2024-03-21 13:01:14 - Zacks Investment Research
All You Need to Know About Oncobiologics (OTLK) Rating Upgrade to Buy
Oncobiologics (OTLK) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
2024-03-06 15:36:32 - InvestorPlace
7 of the Best Speculative Stocks You Can Snag for Less Than $1
I'm about to drop a truth bomb about speculative stocks under $1. Back when I was a freshman in college, the on-campus security officer had this to say: “Tijuana?
2024-02-25 13:37:41 - InvestorPlace
7 Biotech Penny Stocks on the Verge of Clinical Trial Victory
While targeting the therapeutic side of the healthcare sector can be quite lucrative, nothing matches the excitement of biotech penny stocks. Of course, the excitement goes toward both extremes of the emotional spectrum.
2024-01-24 09:11:06 - Zacks Investment Research
Outlook (OTLK) Surges 31% on Regulatory Update for AMD Study
Outlook (OTLK) stock rises after aligning with the FDA regarding the protocols of a non-inferiority study of ONS-5010 for AMD. The study is set to become the basis for BLA resubmission by 2024-end.
2023-11-27 12:17:21 - PennyStocks
Best Penny Stocks To Buy Today? 3 To Watch This Week
Penny stocks, or “stocks under $5,” tend to occupy volatile territory with occasional meteoric runs. While savvy short-term traders eagerly scan for these explosive upside trades, penny stocks remain extremely high-risk.
2023-11-07 14:12:53 - PennyStocks
Invest In Penny Stocks? Is It Worth It & 4 To Watch Now
If you're looking for penny stocks to invest in right now, you've got your work cut out for you. That's because the initial strategy when approaching cheap stocks is to trade them in the short term instead of holding them forever.
2023-11-03 17:09:06 - PennyStocks
3 Penny Stocks To Buy According To Analysts, Targets Up To 365%
Penny stocks, defined as stocks trading under $5 per share, present traders and investors with opportunities for explosive returns. However, the penny stock territory also comes loaded with substantial risks.
2023-11-01 14:11:42 - PennyStocks
5 Most Active Penny Stocks Today & Why They're Moving Now
Penny stocks are the wild west of the stock market. Fast-paced, unpredictable, and laden with potential treasures.